Interferons in relapsing remitting multiple sclerosis.

Interferons in relapsing remitting multiple sclerosis.

Opis bibliograficzny
1. autor:	Goodin, D
Format:	Journal article
Język:	English
Wydane:	2003

Podobne zapisy

Interferons in relapsing remitting multiple sclerosis - Authors' reply
od: Filippini, G, i wsp.
Wydane: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
od: Filippini, G, i wsp.
Wydane: (2003)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
od: Filippini, G, i wsp.
Wydane: (2003)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
od: Dian HE, i wsp.
Wydane: (2014-09-01)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
od: Cocco E, i wsp.
Wydane: (2015-05-01)

Erratum to Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
od: Dian HE
Wydane: (2015-01-01)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is there an odd one Out?
od: Alexis Clapin
Wydane: (2012-04-01)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: is there a one odd out?
od: Alexis Clapin
Wydane: (2012-09-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
od: Làzaro Aurelio Vàzquez Gòmez, i wsp.
Wydane: (2022-10-01)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
od: Wylezinska, M, i wsp.
Wydane: (2003)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
od: Cifelli, A, i wsp.
Wydane: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
od: O.V. Somilo, i wsp.
Wydane: (2024-10-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
od: Burcu Altunrende, i wsp.
Wydane: (2017-12-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
od: Radu Tanasescu, i wsp.
Wydane: (2014-04-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
od: Flavia Salvaterra Cusin, i wsp.
Wydane: (2022-10-01)

Cognitive impairment in relapsing remitting Multiple Sclerosis
od: Saška Roškar
Wydane: (2003-06-01)

Multiple Sclerosis Relapsing Remitting Progressive Type
od: Nora Fitri, i wsp.
Wydane: (2020-12-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
od: V. Casado, i wsp.
Wydane: (2021-07-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
od: Petkau, A, i wsp.
Wydane: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
od: Petkau, A, i wsp.
Wydane: (2004)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
od: Rahil Sadat Shahtaheri, i wsp.
Wydane: (2018-06-01)

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report
od: Taras O. Simaniv, i wsp.
Wydane: (2024-12-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
od: Fernando Rodríguez-Jorge, i wsp.
Wydane: (2024-11-01)

Oxidative stress in relapsing-remitting multiple sclerosis patients
od: Samaneh Sabouri, i wsp.
Wydane: (2023-09-01)

Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
od: V. M. Alifirova, i wsp.
Wydane: (2010-08-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
od: Halil Önder
Wydane: (2019-06-01)

Serum prolactin in patients with relapsing remitting multiple sclerosis
od: Hoda A. Alwakil, i wsp.
Wydane: (2020-07-01)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
od: Burgal María, i wsp.
Wydane: (2010-04-01)

Mild cognitive impairment in relapsing-remitting multiple sclerosis
od: Dimakopoulou Aikaterini, i wsp.
Wydane: (2008-04-01)

Cognitive profile of patients with relapsing remitting multiple sclerosis
od: VIVIAN M. ANDRADE, i wsp.
Wydane: (1999-09-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
od: Damiano Paolicelli, i wsp.
Wydane: (2016-01-01)

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients
od: Chiara D’Angelo, i wsp.
Wydane: (2018-06-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
od: Lesage, E, i wsp.
Wydane: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
od: E. Lesage, i wsp.
Wydane: (2010-01-01)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
od: Lugaresi A, i wsp.
Wydane: (2013-06-01)

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
od: Paty, D, i wsp.
Wydane: (1999)

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
od: Quentin Howlett-Prieto, i wsp.
Wydane: (2023-01-01)

Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients
od: Vinícius O. Boldrini, i wsp.
Wydane: (2022-02-01)

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
od: Forooz Peiravian, i wsp.
Wydane: (2016-09-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
od: Fernando Rodríguez-Jorge, i wsp.
Wydane: (2024-12-01)